PRE-MARKET | November 10, 2016 | Early movers: $KSS, $MET, $COP, $PRTY, $BBY, $CAS, $SHAK, $TWTR, $MYL #Post #ELECTIONS

by Alpha | Nov 10, 2016 | Pre-Market

PRE-MARKET MOVERS

1. SODA:

$SODA SodaStream Q3 Earnings, Sales Beat Estimates – Zacks

2. ZLTQ:

$ZLTQ ZELTIQ Aesthetics Inc. Is Up After Q3 Earnings Surpassed Expectations – RTT

3. ADAP:

$ADAP FDA lifts clinical hold on Adaptimmune cancer trial – Fierce Biotech

4. SHAK:

$SHAK Shake Shack Stock Soars As Profit Doubles – Fox Biz

5. TASR:

$TASR Taser’s Quarterly Profit More Than Doubles – WSJ

6. OMER:

$OMER Omeros Corporation Reports Third Quarter 2016 Financial Results – Biz Wire

7. RL:

$RL Ralph Lauren Tops Q2 EPS by 19c – Street Insider

8. PFE:

$PFE Pfizer wins EU’s approval for Ibrance as Novartis readies rival drug – Reuters

9. PFE:

$PFE Pfizer weighs sale or spin-off of consumer health unit – sources – Reuters

10. TSLA:

$TSLA Tesla’s own numbers show Autopilot has higher crash rate than human drivers – GreenCarReports

11. COP:

$COP ConocoPhillips cuts budget 4 percent, to buy back $3 billion in shares – Reuters

12. YHOO:

$YHOO Yahoo Says Investigating Claim of New Hack of User Data – BBG

13. SCTY:

$SCTY SolarCity’s Hot Third Quarter Shows Why Tesla Wants In – Fortune

14. MYL:

$MYL Mylan ticks higher after reporting earnings and reaffirming guidance – CNBC

15. ALXN:

$ALXN Alexion Pharma to delay quarterly results – MarketWatch

16. GE:

$GE General Electric CEO Immelt Buys 50K Shares – Street Insider

17. VRX:

$VRX Valeant Has Been Subpoenaed Over Its Pharmacy Activities – Fortune

18. MACK:

$MACK Merrimack Pharma Tops Q3 EPS by 4c; Lowers, Narrows FY16 Outlook – SI

19. TWTR:

$TWTR Twitter says COO Adam Bain to leave, Noto to take his place – Reuters

20. TWTR:

$TWTR Twitter Keeps Finding Ways to Look Dysfunctional – BBG Gadfly

21. CCE:

$CCE Coca-Cola European Partners Q3 EPS eur 0.67 – Reuters

22. SLCA:

$SLCA U.S. Silica Prices Public Offering of Common Stock – Nasdaq Read more:

23. AZN:

$AZN AstraZeneca Stocks Slips As Q3 Crestor Sales, Earnings Disappoint – TheStreet

24. TROV:

$TROV TrovaGene Reports Wider-than-Expected Loss in Q3 – Zacks

25. SEDG, SPWR:

$SEDG Solaredge Technologies Inc, SunPower $SPWR Corporation Shares Move Lower On Earnings – ValueWalk

26. NVAX:

$NVAX Novavax Posts Mixed Q3 Results, Announces Restructuring And Update On RSV Program – Benzinga

27. BVX:

$BVX Bovie Medical Announces Primary and Secondary Offerings of Common Stock – Biz Wire

28. AVID:

$AVID Avid Technology Misses Q3 EPS by 19c; Guides Below – Street Insider

29. HLIT:

$HLIT Harmonic Inc. Is Pulling Back After Q3 Loss – RTT

30. ANTH:

$ANTH Anthera Pharma Announces CHABLIS-SC1 Trial Missed Primary Endpoint in Active SLE – SI

UPGRADES

1. ABC:Morgan Stanley Upgrades AmerisourceBergen $ABC to Overweight

2. CHK:$CHK – upgraded to Hold at Jefferies

3. CHTR:MoffettNathanson Upgrades Charter Communications $CHTR to Buy

4. LLL:Barclays Upgrades L-3 Communications $LLL to Overweight

5. LMT:Lockheed Martin Corp. was Upgraded to a Hold Rating at Barclays $LMT

6. LPLA:UBS Upgrades LPL Investment $LPLA to Neutral

7. MPAA:B. Riley Upgrades Motorcar Parts Of America to Buy $MPAA

8. MSFT:Atlantic Equities Upgrades Microsoft $MSFT to Neutral

9. NFX:Societe Generale Upgrades Newfield Exploration $NFX to Buy

10. NOC:$NOC upgraded to Overweight at Barclays – PT raise $270 from $230

11. OAS:Deutsche Bank Upgrades Oasis Petroleum $OAS to Buy

12. PCLN:$PCLN upgraded to Buy at Stifel Nicolaus – PT raise $1.9k from $1.65

13. STON:Raymond James Upgrades Stonemor Partners $STON to Outperform

14. WFT:CLSA Upgrades Weatherford International $WFT to Buy

DOWNGRADES

1. AGFS:Citi Downgrades AgroFresh Solutions $AGFS to Neutral

2. BAS:Deutsche Bank Downgrades Basic Energy Services $BAS to Hold

3. BEAV:Deutsche Bank Downgrades BE Aerospace $BEAV to Hold

4. BEN:Deutsche Bank Downgrades Franklin Resources $BEN to Sell

5. CSX:BMO Capital Downgrades CSX $CSX to Market Perform

6. HOMB:Keefe, Bruyette & Woods Downgrades Home Bancshares $HOMB to Market Perform

7. KND:Kindred Healthcare was Downgraded to a Hold Rating at RBC Capital $KND

8. MS, VRX:Rodman downgrades $vrx to neutral. $ms cuts PT from $42 to $25.

9. RUN:JMP Securities Downgrades Sunrun $RUN to Market Perform

10. SEDG:JMP Securities Downgrades SolarEdge Technologies $SEDG to Market Perform

11. VRX:$VRX downgraded to Neutral at Rodman & Renshaw – PT cut $23 from $81, maintains Overweight rating at Morgan Stanley – PT cut $25 from $42

12. VSLR:JMP Securities Downgrades Vivint Solar $VSLR to Market Perform

13. WCG:JPMorgan Downgrades WellCare Health Plans $WCG to Neutral

14. WK:Credit Suisse Downgrades Workiva $WK to Neutral

EARNINGS

1. NAT:$NAT reports FQ3 earnings of -8c EPS and $45.86M Revs –

2. NICE:$NICE reports FQ3 earnings of 83c EPS and $240.29M Revs –

3. AZN:$AZN reports FQ3 earnings of $1.32 EPS and $5.70B Revs –

4. PRGO:$PRGO reports FQ3 earnings of $1.65 EPS and $1.33B Revs –

5. WIX:$WIX reports FQ3 earnings of -4c EPS and $75.61M Revs –

6. HIMX:$HIMX reports FQ3 earnings of 12c EPS and $218.08M Revs –

7. GLF:$GLF reports FQ3 earnings of $-1.05 EPS and $27.82M Revs –

8. MMS:$MMS reports FQ4 earnings of 77c EPS and $623.09M Revs –

9. BCEI:$BCEI reports FQ3 earnings of -35c EPS and $49.33M Revs –

10. PRTY:$PRTY reports FQ3 earnings of 12c EPS and $556.95M Revs –

11. PRTY:$PRTY reports inline with the Estimize EPS Consensus and misses the Estimize Revenue Consensus by $20.77M –

12. KSS:$KSS reports FQ3 earnings of 80c EPS and $4.33B Revs –

13. VSTO:$VSTO reports FQ2 earnings of 74c EPS and $684.31M Revs –

14. BRKS:$BRKS reports FQ4 earnings of 22c EPS and $157.55M Revs –

15. SODA:$SODA reports FQ3 earnings of 69c EPS and $124.23M Revs –

16. CCE:$CCE reports FQ3 earnings of 72c EPS and $3.26B Revs –

17. RL:$RL reports FQ2 earnings of $1.90 EPS and $1.82B Revs –

18. PNK:$PNK reports FQ3 earnings of -1c EPS and $595.17M Revs –

Trending Social Alerts

1. BMY:Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus $BMY

2. ANTH:$ANTH Blisibimod CHABLIS-SC1 Phase 3 Study Did Not Achieve the Primary Endpoint in Patients With Active Systemic Lupus Erythematosus #Fail

3. HALO:$HALO Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

4. IBB:$XBI up 2.7% $IBB up 1.93% in pm

5. SODA:$SODA Reports Q3 EPS $0.69 vs. Est. $0.23, Rev. $124.2M vs. Est. $115M – double digit growth 🙂

6. SGEN:$SGEN Receives FDA Breakthrough Therapy Designation for ADCETRIS® in Mycosis Fungoides & Primary Cutaneous Anaplastic Large Cell Lymphoma

7. MNKD:.@AdamSinger Neither do I, but it’s a bizarre announcement. Does $MNKD have compromising photos or similar?

8. CELG:@tgtxdough $IBB $CELG coiled spring of money flow may need to shift back over to biotech.

9. KSS:Kohl’s Reports Q3 Adj. EPS $0.80 vs $0.70 Est., Sales $4.327B vs $4.33B Est. $KSS

10. M:$KSS Father Christmas makes a bear skin rug. $M up next…

11. TUBE:$TUBE Adobe $ADBE to acquire TubeMogul for $14/sh

12. RDHL:$RDHL Reports Positive FDA Type B Meeting on RHB-105 for H. Pylori Infection Ahead of Confirmatory Phase III Study

Trending News Headlines

1. Six thoughts on President Trump and the durability of the biotech stock rally

Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?

2. Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus

It’s not all checkpoints all the time at Bristol-Myers Squibb. The big biotech has been ramping up an ambitious effort in fibrosis and NASH and this morning it’s taking the wraps off another deal in the field, paying $100 million to Japan’s Nitto Denko for an early-stage drug candidate that

3. Opdivo (nivolumab) Demonstrates Overall Survival Benefit in Patients With Unresectable Advanced or Recurrent Gastric Cancer in Phase 3 Study

Opdivo is the first and only Immuno-Oncology agent to demonstrate overall survival advantage in patients with unresectable advanced or recurrent gastric cancer refractory to, or intolerant of, standard therapy Bristol-Myers Squibb Company (NYSE:BMY) announced today that ONO-4538-12, a Phase 3, randomized, double-blind clinical trial evaluating the efficacy and safety of Opdivo (nivolumab) in patients with unresectable advanced or recurrent gastric cancer refractory to, or intolerant of, standard therapy, met its primary endpoint of overall survival (OS). Ono Pharmaceutical Co. Ltd. of Japan , Bristol-Myers Squibb’s development partner for Opdivo , conducted the ONO-4538-12 trial. The companies will work with investigators on the future presentation of the study results. Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb, commented, “Patients with advanced or recurrent gastric cancer generally have a poor prognosis, and there are currently no standard-of-care

4. Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types

Phase 1b/2 studies will evaluate Halozyme’s investigational drug, PEGPH20 with Genentech’s anti-PDL1 Tecentriq® (atezolizumab) Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, and Genentech, a member of the Roche Group , today announced an agreement to collaborate on clinical studies evaluating up to eight different tumor types beginning in 2017. The first study will be a Phase 1b/2 open-label, multi-arm randomized global study, led by Genentech to evaluate their cancer immunotherapy Tecentriq® (atezolizumab), an anti-PD-L1 monoclonal antibody, in combination with Halozyme’s investigational drug, PEGPH20 in six tumor types. Halozyme will supply drug only for the Genentech study. This study will have an initial focus on gastrointestinal malignancies, including pancreatic and gastric cancers. The second study will be a Phase 1b open-label randomized study led by Halozyme to assess Tecentriq in combination with PEGPH20

5. Andy Biotech on Twitter

“$AZN discontinues its Anti-CD19 in DLBCL and Anti-ANG2 in solid tumors. $JUNO $KITE $SGEN $XNCR”

6. Katy Perry Ditches Alibaba’s Concert After Anti-Trump Tweets

Pop star Katy Perry has pulled out of a star-studded extravaganza put on by China’s largest online retailer.

7. Tesla’s own numbers show Autopilot has higher crash rate than human drivers

A couple of weeks ago, I wrote about Tesla’s claim that its Autopilot driver-assistance software is safer than a human driver. After a fatal Autopilot crash last May, the company said the death was the first in 130 million miles of Autopilot driving—and noted that, “among all…

8. AstraZeneca sees big healthcare changes under Trump

Drugmaker AstraZeneca (AZN.L) expects major U.S. healthcare changes after Donald Trump’s election victory but its chief executive warned on Thursday that pricing pressures in the world’s biggest drugs market would not go away.

9. IEA sees global market awash with oil in 2017 if no OPEC cut

The oil market risks running another surplus in 2017 without an output cut from OPEC, as producers around the globe ramp up supply and demand growth falters, the International Energy Agency said on Thursday.

10. U.S. should have joined China-led infrastructure bank: Trump adviser

A top adviser of U.S. President-elect Donald Trump lashed out at the Obama administration for failing to embrace the China-led Asian Infrastructure Investment Bank (AIIB), suggesting a possible policy shift when Trump takes office in January.

Technology News

1. It’s about time you got to know a bit about Mike Pence—and how terrible he’d be for Silicon Valley:

2. Reminder: Facebook has created a product that has made it profitable for people to lie to you with fake news.

3. The future of news: Macedonian schoolchildren making $$$ by writing fake pro-Trump stories that go viral on Facebook

4. Trump, when asked about hacking his political enemies, said “I wish I had that power.” With NSA, he’ll soon will.

5. Trump’s NASA looks good for human space exploration and terrible for Earth science

6. A Silicon Valley investor said he wanted California to become its own nation if Trump won

7. Donald Trump’s win is a reminder of Facebook’s power to transform society, and often not for the better

8. “the best way to generate shares on Facebook is to publish sensationalist and often false content”

9. Silicon Valley and tech industry’s relationship with government is set to shift under Trump. @fmanjoo examines how:

10. I wrote a thing about Silicon Valley getting blindsided, and where tech goes from here

Early movers: KSS, MET, COP, PRTY, BBY, CAS, SHAK, TWTR, MYL & more

Check out which companies are making headlines before the bell: Kohl’s – The retailer reported adjusted quarterly profit of 80 cents per share, 10 cents a share above forecasts. Revenue was very slightly above estimates. Same-store sales did fall by 1.7 percent, but that drop was in line with analysts’ projections.

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Share This

Share this post with your friends!